We’re thrilled to share that Biocytogen will attend Fierce Pharma Engage from April 22nd - 24th in San Diego, CA. Come join us for two days of interactive sessions and hand-on learning with experts from pharma and biotech. Let's unlock innovation and build real solutions together!
What is Fierce Pharma Engage?
Fierce Pharma Engage is an exclusive conference for senior leaders in pharma and biotech marketing, PR & communications, and business development & licensing. The event provides a dynamic setting focused on strategic collaborations and meaningful connections. The 1:1 meeting model allows for a more personalized experience, making this a fantastic networking opportunity.
Event Overview
Date: April 22nd - 24th, 2026
Venue: Hilton San Diego Bayfront, 1 Park Blvd, San Diego, CA 92101
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of pharma and biotech together, we look forward to meeting you in San Diego, CA!
